Best of the Blog: IN VIVO, January 2009
Executive Summary
Best of the Blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In January, Windhover's editorial staff posted 48 articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Highlights included our ongoing coverage of Pfizer's acquisition of Wyeth as well as dispatches from the JP Morgan meeting in San Francisco. And we awarded IN VIVO Blog's Deal of the Year. Here are a few of our favorite blog posts and excerpts for stories not covered elsewhere in this month's IN VIVO.
You may also be interested in...
GSK Tries to Mimic Real-World Biotech
Not satisfied with its R&D experiments to date, GSK has taken its most radical step yet toward re-creating biotech within its walls: even smaller units complete with investment boards occupied by external VCs and CEOs and milestone-based funding and external VCs.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.